Which has preferable valuation & earnings, LUCD or SIBN?

SiBone has higher revenue and earnings than Lucid Diagnostics. SiBone is trading at a lower price-to-earnings ratio than Lucid Diagnostics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Lucid Diagnostics $5.13M 35.90 -$58.01M -$0.47 N/A SiBone $206.22M 3.57 -$18.90M -$0.39 N/A

Is LUCD or SIBN more profitable?

SiBone has a net margin of -8.10% compared to Lucid Diagnostics' net margin of -876.72%. Lucid Diagnostics' return on equity of 0.00% beat SiBone's return on equity. Company Net Margins Return on Equity Return on Assets Lucid Diagnostics -876.72% N/A -116.26% SiBone -8.10% -9.56% -7.06%

Does the media prefer LUCD or SIBN?

In the previous week, SiBone had 2 more articles in the media than Lucid Diagnostics. MarketBeat recorded 4 mentions for SiBone and 2 mentions for Lucid Diagnostics. SiBone's average media sentiment score of 1.31 beat Lucid Diagnostics' score of 0.58 indicating that SiBone is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Lucid Diagnostics 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive SiBone 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to LUCD or BBNX?

In the previous week, Beta Bionics had 2 more articles in the media than Lucid Diagnostics. MarketBeat recorded 4 mentions for Beta Bionics and 2 mentions for Lucid Diagnostics. Beta Bionics' average media sentiment score of 1.80 beat Lucid Diagnostics' score of 0.58 indicating that Beta Bionics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Lucid Diagnostics 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Beta Bionics 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Is CBLL or LUCD more profitable?

CeriBell has a net margin of -63.51% compared to Lucid Diagnostics' net margin of -876.72%. Lucid Diagnostics' return on equity of 0.00% beat CeriBell's return on equity. Company Net Margins Return on Equity Return on Assets CeriBell -63.51% -38.19% -30.92% Lucid Diagnostics -876.72% N/A -116.26%

Does the media prefer CBLL or LUCD?

In the previous week, CeriBell had 1 more articles in the media than Lucid Diagnostics. MarketBeat recorded 3 mentions for CeriBell and 2 mentions for Lucid Diagnostics. CeriBell's average media sentiment score of 1.19 beat Lucid Diagnostics' score of 0.58 indicating that CeriBell is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CeriBell 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Lucid Diagnostics 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to LUCD or SSII?

In the previous week, SS Innovations International had 7 more articles in the media than Lucid Diagnostics. MarketBeat recorded 9 mentions for SS Innovations International and 2 mentions for Lucid Diagnostics. Lucid Diagnostics' average media sentiment score of 0.58 beat SS Innovations International's score of 0.51 indicating that Lucid Diagnostics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Lucid Diagnostics 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive SS Innovations International 3 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is LUCD or SGP more profitable?

Spyglass Pharma has a net margin of 0.00% compared to Lucid Diagnostics' net margin of -876.72%. Company Net Margins Return on Equity Return on Assets Lucid Diagnostics -876.72% N/A -116.26% Spyglass Pharma N/A N/A N/A

Does the media refer more to LUCD or SGP?

In the previous week, Spyglass Pharma had 7 more articles in the media than Lucid Diagnostics. MarketBeat recorded 9 mentions for Spyglass Pharma and 2 mentions for Lucid Diagnostics. Lucid Diagnostics' average media sentiment score of 0.58 beat Spyglass Pharma's score of 0.30 indicating that Lucid Diagnostics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Lucid Diagnostics 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Spyglass Pharma 1 Very Positive mention(s) 0 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Lucid Diagnostics (LUCD) Competitors

$0.91 -0.04 (-4.01%)

Closing price 07/24/2026 04:00 PM Eastern

Extended Trading

$0.92 +0.02 (+1.92%)

As of 07/24/2026 07:34 PM Eastern

Compare

LUCD vs. SIBN, BBNX, CBLL, SSII, and SGP

Should you buy Lucid Diagnostics stock or one of its competitors? MarketBeat compares Lucid Diagnostics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Lucid Diagnostics include SiBone (SIBN), Beta Bionics (BBNX), CeriBell (CBLL), SS Innovations International (SSII), and Spyglass Pharma (SGP). These companies are all part of the "medical equipment" industry.

How does Lucid Diagnostics compare to SiBone?

Lucid Diagnostics (NASDAQ:LUCD) and SiBone (NASDAQ:SIBN) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, valuation, earnings, analyst recommendations, media sentiment, profitability, institutional ownership and risk.

SiBone has a net margin of -8.10% compared to Lucid Diagnostics' net margin of -876.72%. Lucid Diagnostics' return on equity of 0.00% beat SiBone's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lucid Diagnostics	-876.72%	N/A	-116.26%
SiBone	-8.10%	-9.56%	-7.06%

In the previous week, SiBone had 2 more articles in the media than Lucid Diagnostics. MarketBeat recorded 4 mentions for SiBone and 2 mentions for Lucid Diagnostics. SiBone's average media sentiment score of 1.31 beat Lucid Diagnostics' score of 0.58 indicating that SiBone is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lucid Diagnostics	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
SiBone	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

SiBone has higher revenue and earnings than Lucid Diagnostics. SiBone is trading at a lower price-to-earnings ratio than Lucid Diagnostics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lucid Diagnostics	$5.13M	35.90	-$58.01M	-$0.47	N/A
SiBone	$206.22M	3.57	-$18.90M	-$0.39	N/A

Lucid Diagnostics currently has a consensus target price of $4.19, indicating a potential upside of 361.38%. SiBone has a consensus target price of $23.50, indicating a potential upside of 41.40%. Given Lucid Diagnostics' higher probable upside, analysts plainly believe Lucid Diagnostics is more favorable than SiBone.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lucid Diagnostics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60
SiBone	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

74.0% of Lucid Diagnostics shares are held by institutional investors. Comparatively, 98.1% of SiBone shares are held by institutional investors. 6.9% of Lucid Diagnostics shares are held by company insiders. Comparatively, 4.0% of SiBone shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Lucid Diagnostics has a beta of 1.07, meaning that its share price is 7% more volatile than the broader market. Comparatively, SiBone has a beta of 0.67, meaning that its share price is 33% less volatile than the broader market.

Summary

SiBone beats Lucid Diagnostics on 10 of the 16 factors compared between the two stocks.

How does Lucid Diagnostics compare to Beta Bionics?

Lucid Diagnostics (NASDAQ:LUCD) and Beta Bionics (NASDAQ:BBNX) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, earnings, risk, profitability, dividends, valuation and analyst recommendations.

74.0% of Lucid Diagnostics shares are owned by institutional investors. 6.9% of Lucid Diagnostics shares are owned by company insiders. Comparatively, 5.3% of Beta Bionics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Lucid Diagnostics has a beta of 1.07, indicating that its share price is 7% more volatile than the broader market. Comparatively, Beta Bionics has a beta of 3.04, indicating that its share price is 204% more volatile than the broader market.

Beta Bionics has a net margin of -60.27% compared to Lucid Diagnostics' net margin of -876.72%. Lucid Diagnostics' return on equity of 0.00% beat Beta Bionics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lucid Diagnostics	-876.72%	N/A	-116.26%
Beta Bionics	-60.27%	-23.00%	-20.55%

Lucid Diagnostics currently has a consensus price target of $4.19, indicating a potential upside of 361.38%. Beta Bionics has a consensus price target of $20.30, indicating a potential upside of 28.08%. Given Lucid Diagnostics' higher possible upside, research analysts clearly believe Lucid Diagnostics is more favorable than Beta Bionics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lucid Diagnostics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60
Beta Bionics	1 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.64

In the previous week, Beta Bionics had 2 more articles in the media than Lucid Diagnostics. MarketBeat recorded 4 mentions for Beta Bionics and 2 mentions for Lucid Diagnostics. Beta Bionics' average media sentiment score of 1.80 beat Lucid Diagnostics' score of 0.58 indicating that Beta Bionics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lucid Diagnostics	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Beta Bionics	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Lucid Diagnostics has higher earnings, but lower revenue than Beta Bionics. Beta Bionics is trading at a lower price-to-earnings ratio than Lucid Diagnostics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lucid Diagnostics	$5.13M	35.90	-$58.01M	-$0.47	N/A
Beta Bionics	$110.24M	6.41	-$73.20M	-$1.51	N/A

Summary

Beta Bionics beats Lucid Diagnostics on 9 of the 17 factors compared between the two stocks.

How does Lucid Diagnostics compare to CeriBell?

CeriBell (NASDAQ:CBLL) and Lucid Diagnostics (NASDAQ:LUCD) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, risk, earnings, profitability, dividends, valuation, institutional ownership and media sentiment.

CeriBell has higher revenue and earnings than Lucid Diagnostics. CeriBell is trading at a lower price-to-earnings ratio than Lucid Diagnostics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CeriBell	$89.06M	7.20	-$53.41M	-$1.63	N/A
Lucid Diagnostics	$5.13M	35.90	-$58.01M	-$0.47	N/A

In the previous week, CeriBell had 1 more articles in the media than Lucid Diagnostics. MarketBeat recorded 3 mentions for CeriBell and 2 mentions for Lucid Diagnostics. CeriBell's average media sentiment score of 1.19 beat Lucid Diagnostics' score of 0.58 indicating that CeriBell is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CeriBell	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Lucid Diagnostics	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

CeriBell has a net margin of -63.51% compared to Lucid Diagnostics' net margin of -876.72%. Lucid Diagnostics' return on equity of 0.00% beat CeriBell's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CeriBell	-63.51%	-38.19%	-30.92%
Lucid Diagnostics	-876.72%	N/A	-116.26%

74.0% of Lucid Diagnostics shares are held by institutional investors. 20.1% of CeriBell shares are held by company insiders. Comparatively, 6.9% of Lucid Diagnostics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

CeriBell has a beta of 0.77, indicating that its stock price is 23% less volatile than the broader market. Comparatively, Lucid Diagnostics has a beta of 1.07, indicating that its stock price is 7% more volatile than the broader market.

CeriBell currently has a consensus target price of $22.20, indicating a potential upside of 31.28%. Lucid Diagnostics has a consensus target price of $4.19, indicating a potential upside of 361.38%. Given Lucid Diagnostics' higher possible upside, analysts plainly believe Lucid Diagnostics is more favorable than CeriBell.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CeriBell	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83
Lucid Diagnostics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60

Summary

CeriBell beats Lucid Diagnostics on 9 of the 16 factors compared between the two stocks.

How does Lucid Diagnostics compare to SS Innovations International?

Lucid Diagnostics (NASDAQ:LUCD) and SS Innovations International (NASDAQ:SSII) are both small-cap medical equipment companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, risk, analyst recommendations, profitability, earnings, media sentiment, institutional ownership and valuation.

In the previous week, SS Innovations International had 7 more articles in the media than Lucid Diagnostics. MarketBeat recorded 9 mentions for SS Innovations International and 2 mentions for Lucid Diagnostics. Lucid Diagnostics' average media sentiment score of 0.58 beat SS Innovations International's score of 0.51 indicating that Lucid Diagnostics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lucid Diagnostics	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
SS Innovations International	3 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

SS Innovations International has a net margin of -20.69% compared to Lucid Diagnostics' net margin of -876.72%. Lucid Diagnostics' return on equity of 0.00% beat SS Innovations International's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lucid Diagnostics	-876.72%	N/A	-116.26%
SS Innovations International	-20.69%	-23.00%	-13.18%

Lucid Diagnostics has a beta of 1.07, indicating that its share price is 7% more volatile than the broader market. Comparatively, SS Innovations International has a beta of -1.96, indicating that its share price is 296% less volatile than the broader market.

Lucid Diagnostics currently has a consensus price target of $4.19, indicating a potential upside of 361.38%. SS Innovations International has a consensus price target of $7.00, indicating a potential upside of 101.73%. Given Lucid Diagnostics' stronger consensus rating and higher possible upside, equities analysts clearly believe Lucid Diagnostics is more favorable than SS Innovations International.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lucid Diagnostics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60
SS Innovations International	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

74.0% of Lucid Diagnostics shares are owned by institutional investors. 6.9% of Lucid Diagnostics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

SS Innovations International has higher revenue and earnings than Lucid Diagnostics. SS Innovations International is trading at a lower price-to-earnings ratio than Lucid Diagnostics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lucid Diagnostics	$5.13M	35.90	-$58.01M	-$0.47	N/A
SS Innovations International	$48.47M	14.33	-$12.13M	-$0.05	N/A

Summary

Lucid Diagnostics beats SS Innovations International on 10 of the 16 factors compared between the two stocks.

How does Lucid Diagnostics compare to Spyglass Pharma?

Lucid Diagnostics (NASDAQ:LUCD) and Spyglass Pharma (NASDAQ:SGP) are both small-cap medical equipment companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, institutional ownership, risk, profitability, media sentiment, valuation, analyst recommendations and earnings.

In the previous week, Spyglass Pharma had 7 more articles in the media than Lucid Diagnostics. MarketBeat recorded 9 mentions for Spyglass Pharma and 2 mentions for Lucid Diagnostics. Lucid Diagnostics' average media sentiment score of 0.58 beat Spyglass Pharma's score of 0.30 indicating that Lucid Diagnostics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lucid Diagnostics	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Spyglass Pharma	1 Very Positive mention(s)	0 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Lucid Diagnostics presently has a consensus price target of $4.19, indicating a potential upside of 361.38%. Spyglass Pharma has a consensus price target of $45.00, indicating a potential upside of 119.62%. Given Lucid Diagnostics' higher possible upside, analysts plainly believe Lucid Diagnostics is more favorable than Spyglass Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lucid Diagnostics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60
Spyglass Pharma	0 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.83

Spyglass Pharma has a net margin of 0.00% compared to Lucid Diagnostics' net margin of -876.72%.

Company	Net Margins	Return on Equity	Return on Assets
Lucid Diagnostics	-876.72%	N/A	-116.26%
Spyglass Pharma	N/A	N/A	N/A

Spyglass Pharma has lower revenue, but higher earnings than Lucid Diagnostics. Spyglass Pharma is trading at a lower price-to-earnings ratio than Lucid Diagnostics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lucid Diagnostics	$5.13M	35.90	-$58.01M	-$0.47	N/A
Spyglass Pharma	N/A	N/A	N/A	-$6.41	N/A

Summary

Lucid Diagnostics beats Spyglass Pharma on 7 of the 12 factors compared between the two stocks.

Get Lucid Diagnostics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding LUCD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

LUCD vs. The Competition

Export

Metric	Lucid Diagnostics	MED INSTRUMENTS Industry	Medical Sector	NASDAQ Exchange
Market Cap	$184.30M	$7.29B	$6.87B	$12.26B
Dividend Yield	N/A	1.33%	2.67%	9.79%
P/E Ratio	-1.93	48.63	27.14	23.64
Price / Sales	35.90	96.87	517.06	88.99
Price / Cash	N/A	25.71	50.54	59.64
Price / Book	-2.93	6.73	10.28	6.07
Net Income	-$58.01M	$162.27M	$3.60B	$331.99M
7 Day Performance	-4.48%	-5.05%	-1.27%	-0.63%
1 Month Performance	-12.73%	-5.86%	-0.37%	-2.00%
1 Year Performance	-18.23%	-2.88%	18.30%	13.62%

Lucid Diagnostics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
LUCD Lucid Diagnostics	3.1908 of 5 stars	$0.91 -4.0%	$4.19 +361.4%	-17.5%	$184.30M	$5.13M	N/A	70
SIBN SiBone	3.7156 of 5 stars	$16.91 -5.3%	$23.00 +36.0%	-4.3%	$791.64M	$200.93M	N/A	350	News Coverage Analyst Upgrade
BBNX Beta Bionics	3.2371 of 5 stars	$16.86 -0.5%	$20.10 +19.2%	+9.8%	$755.32M	$100.25M	N/A	294	News Coverage
CBLL CeriBell	3.1197 of 5 stars	$19.13 -2.0%	$22.20 +16.0%	+9.9%	$740.64M	$89.06M	N/A	N/A	Positive News
SSII SS Innovations International	1.6904 of 5 stars	$3.67 +0.8%	$7.00 +90.7%	-51.8%	$728.48M	$42.49M	N/A	4	Short Interest Increase High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:LUCD) was last updated on 7/25/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Lucid Diagnostics (LUCD) Competitors

LUCD vs. SIBN, BBNX, CBLL, SSII, and SGP

How does Lucid Diagnostics compare to SiBone?

Summary

How does Lucid Diagnostics compare to Beta Bionics?

Summary

How does Lucid Diagnostics compare to CeriBell?

Summary

How does Lucid Diagnostics compare to SS Innovations International?

Summary

How does Lucid Diagnostics compare to Spyglass Pharma?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LUCD vs. The Competition

Lucid Diagnostics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Lucid Diagnostics (LUCD) Competitors

LUCD vs. SIBN, BBNX, CBLL, SSII, and SGP

How does Lucid Diagnostics compare to SiBone?

Is LUCD or SIBN more profitable?

Does the media prefer LUCD or SIBN?

Which has preferable valuation & earnings, LUCD or SIBN?

Do analysts prefer LUCD or SIBN?

Do institutionals & insiders have more ownership in LUCD or SIBN?

Which has more volatility and risk, LUCD or SIBN?

Summary

How does Lucid Diagnostics compare to Beta Bionics?

Do institutionals and insiders believe in LUCD or BBNX?

Which has more volatility & risk, LUCD or BBNX?

Is LUCD or BBNX more profitable?

Do analysts prefer LUCD or BBNX?

Does the media refer more to LUCD or BBNX?

Which has preferable valuation & earnings, LUCD or BBNX?

Summary

How does Lucid Diagnostics compare to CeriBell?

Which has preferable valuation and earnings, CBLL or LUCD?

Does the media prefer CBLL or LUCD?

Is CBLL or LUCD more profitable?

Do institutionals and insiders have more ownership in CBLL or LUCD?

Which has more volatility and risk, CBLL or LUCD?

Do analysts recommend CBLL or LUCD?

Summary

How does Lucid Diagnostics compare to SS Innovations International?

Does the media refer more to LUCD or SSII?

Is LUCD or SSII more profitable?

Which has more volatility & risk, LUCD or SSII?

Do analysts rate LUCD or SSII?

Do insiders and institutionals have more ownership in LUCD or SSII?

Which has preferable valuation & earnings, LUCD or SSII?

Summary

How does Lucid Diagnostics compare to Spyglass Pharma?

Does the media refer more to LUCD or SGP?

Do analysts prefer LUCD or SGP?

Is LUCD or SGP more profitable?

Which has higher valuation and earnings, LUCD or SGP?

Do insiders & institutionals believe in LUCD or SGP?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LUCD vs. The Competition

Lucid Diagnostics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools